Global and United States Cutaneous Leishmaniasis Drugs Market Report & Forecast 2022-2028
Cutaneous leishmaniasis is the most common syndrome and can produce ulcers that have the potential of stimulating a periosteal reaction if the ulcer occurs near bone.
Leishmaniasis, a protozoal infection transmitted by sandfly bite, produces a clinical spectrum of disease ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. Leishmaniasis is endemic in regions of Africa, the Middle East, south Asia, southern Europe, northern South America, and Central America. There has been an increase in imported leishmaniasis into developed, non-endemic countries due to increasing global travel. While pentavalent antimonials have been the mainstay of antileishmanial treatment for decades, newer therapeutic options have become available for all forms of infection, including liposomal amphotericin B, miltefosine, fluconazole, and ketoconazole.
Market Analysis and Insights: Global and United States Cutaneous Leishmaniasis Drugs Market
This report focuses on global and United States Cutaneous Leishmaniasis Drugs market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Cutaneous Leishmaniasis Drugs market size is estimated to be worth US$ 45 million in 2022 and is forecast to a readjusted size of US$ 57 million by 2028 with a CAGR of 4.1% during the review period. Fully considering the economic change by this health crisis, by Type, Pentavalent Antimonials accounting for % of the Cutaneous Leishmaniasis Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospital was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
Global Cutaneous Leishmaniasis Drugs Sales key players include Sanofi, Albert David, Albert David, etc. Global top three manufacturers hold a share over 60%. Middle East and Africa is the largest market, with a share about 40%, followed by Asia-Pacific, and South America. In terms of product, Pentavalent Antimonials is the largest segment, with a share over 43%. In Cutaneous Leishmaniasis Drugs market, the Hospital holds an important share in terms of Application, followed by Retail Pharmacy, etc.
Global Cutaneous Leishmaniasis Drugs Scope and Market Size
Cutaneous Leishmaniasis Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Cutaneous Leishmaniasis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Cutaneous Leishmaniasis Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Pentavalent Antimonials
Antifungal Drugs
Anti-Leishmanial/Antimicrobial Drugs
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
GSK
Novartis
Sanofi
Gilead Sciences
Bristol-Myers Squibb
Albert David
Profounda
Knight Therapeutics
Pfizer
Xinhua Pharma
Leishmaniasis, a protozoal infection transmitted by sandfly bite, produces a clinical spectrum of disease ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. Leishmaniasis is endemic in regions of Africa, the Middle East, south Asia, southern Europe, northern South America, and Central America. There has been an increase in imported leishmaniasis into developed, non-endemic countries due to increasing global travel. While pentavalent antimonials have been the mainstay of antileishmanial treatment for decades, newer therapeutic options have become available for all forms of infection, including liposomal amphotericin B, miltefosine, fluconazole, and ketoconazole.
Market Analysis and Insights: Global and United States Cutaneous Leishmaniasis Drugs Market
This report focuses on global and United States Cutaneous Leishmaniasis Drugs market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Cutaneous Leishmaniasis Drugs market size is estimated to be worth US$ 45 million in 2022 and is forecast to a readjusted size of US$ 57 million by 2028 with a CAGR of 4.1% during the review period. Fully considering the economic change by this health crisis, by Type, Pentavalent Antimonials accounting for % of the Cutaneous Leishmaniasis Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Hospital was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
Global Cutaneous Leishmaniasis Drugs Sales key players include Sanofi, Albert David, Albert David, etc. Global top three manufacturers hold a share over 60%. Middle East and Africa is the largest market, with a share about 40%, followed by Asia-Pacific, and South America. In terms of product, Pentavalent Antimonials is the largest segment, with a share over 43%. In Cutaneous Leishmaniasis Drugs market, the Hospital holds an important share in terms of Application, followed by Retail Pharmacy, etc.
Global Cutaneous Leishmaniasis Drugs Scope and Market Size
Cutaneous Leishmaniasis Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Cutaneous Leishmaniasis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Cutaneous Leishmaniasis Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Pentavalent Antimonials
Antifungal Drugs
Anti-Leishmanial/Antimicrobial Drugs
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
GSK
Novartis
Sanofi
Gilead Sciences
Bristol-Myers Squibb
Albert David
Profounda
Knight Therapeutics
Pfizer
Xinhua Pharma
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
